2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.40 USD
+0.06 (1.38%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TSVT 4.40 +0.06(1.38%)
Will TSVT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TSVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSVT
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
TSVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
Other News for TSVT
Bristol-Myers raises outlook ahead of consensus after Q3 beat
Notable Two Hundred Day Moving Average Cross - TSVT
TD Cowen Sticks to Its Hold Rating for 2seventy bio (TSVT)
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance